Geron (GERN) Non-Current Debt (2011 - 2026)
Geron's (GERN) quarterly Non-Current Debt came in at $119.8 million in Q1 2026, up 0.93% year-on-year from $118.7 million in Q1 2025, and little changed quarter-over-quarter from $119.5 million in Q4 2025.
Geron (GERN) Non-Current Debt (2011 - 2026) Analysis & Trends
Geron has disclosed Non-Current Debt across 8 years of filings, most recently posting $119.8 million for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $119.8 million, up 0.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $119.8 million (up 0.93% YoY), and the FY2025 annual result was $119.5 million, up 0.9% from the prior year.
- Non-Current Debt came in at $119.8 million for Q1 2026 at Geron, roughly flat from $119.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $119.8 million in Q1 2026 to a low of $11.2 million in Q1 2024.
- The 5-year median for Non-Current Debt is $45.3 million (2022), against an average of $64.4 million.
- Across the five-year window, Non-Current Debt plunged 78.17% in 2024 and soared 958.28% in 2025, its largest moves.
- Geron's Non-Current Debt stood at $30.2 million in 2022, then advanced by 16.02% to $35.1 million in 2023, then soared by 238.01% to $118.5 million in 2024, then climbed by 0.9% to $119.5 million in 2025, then grew by 0.24% to $119.8 million in 2026.
- The last three Non-Current Debt figures came in at $119.8 million (Q1 2026), $119.5 million (Q4 2025), and $119.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Geron | 729,618.77 | 729,618.77 | - | 119.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.83 Mn |
| Mar 31, 2026 | 119.83 Mn |
| Dec 31, 2025 | 119.55 Mn |
| Dec 31, 2025 | 119.55 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Sep 30, 2025 | 119.26 Mn |
| Jun 30, 2025 | 118.99 Mn |
| Jun 30, 2025 | 118.99 Mn |
| Mar 31, 2025 | 118.73 Mn |
| Mar 31, 2025 | 118.73 Mn |
| Dec 31, 2024 | 118.48 Mn |
| Dec 31, 2024 | 118.48 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Mar 31, 2024 | 11.22 Mn |
| Mar 31, 2024 | 11.22 Mn |
| Dec 31, 2023 | 35.05 Mn |
| Dec 31, 2023 | 35.05 Mn |